Janet R. Vos

915 citations

28 papers · 220 indexed · h-index 9

Co-authors: Nicoline Hoogerbrugge Janneke Schuurs-Hoeijmakers Marian J.E. Mourits Geertruida H. de Bock Jan C. Oosterwijk Arjen R. Mensenkamp Marjolijn J. L. Ligtenberg Margreet G.E.M. Ausems
Topics: BRCA gene mutations in cancer (13 papers)Ovarian cancer diagnosis and treatment (7 papers)PI3K/AKT/mTOR signaling in cancer (7 papers)
Cited by: Reproductive Medicine Cancer Research Genetics
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaJNCI Journal of the National Cancer Institute
Partner nations: Netherlands Italy Philippines

In The Last Decade

Janet R. Vos

25 papers receiving 217 citations

Peers

Countries citing papers authored by Janet R. Vos

Since Specialization

Citations

This map shows the geographic impact of Janet R. Vos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet R. Vos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet R. Vos more than expected).

Fields of papers citing papers by Janet R. Vos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet R. Vos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet R. Vos. The network helps show where Janet R. Vos may publish in the future.

Co-authorship network of co-authors of Janet R. Vos

This figure shows the co-authorship network connecting the top 25 collaborators of Janet R. Vos. A scholar is included among the top collaborators of Janet R. Vos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet R. Vos. Janet R. Vos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Increased frequency of infections and autoimmune disease in adults with PTEN Hamartoma Tumour Syndrome 2024 ·European Journal of Medical Genetics ·(unknown),Janet R. Vos,(unknown),Janneke Schuurs-Hoeijmakers,Jolanda Schieving,Nicoline Hoogerbrugge	2
2	Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single‐center study 2024 ·International Journal of Cancer ·(unknown),(unknown),Rachel S. van der Post,Arjen R. Mensenkamp,Jolanda Schieving,(unknown),Janneke Schuurs-Hoeijmakers,Nicoline Hoogerbrugge,Janet R. Vos	2
3	Genomic instability in non–breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2 2024 ·JNCI Journal of the National Cancer Institute ·(unknown),Rachel S. van der Post,Janet R. Vos,Arjen R. Mensenkamp,(unknown),(unknown),(unknown),Michiel Oorsprong,Tom Hofste,Michiel Simons,Irıs D. Nagtegaal,Nicoline Hoogerbrugge,Richarda M. de Voer,Marjolijn J. L. Ligtenberg	0
4	Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome 2023 ·JNCI Journal of the National Cancer Institute ·(unknown),Rachel S. van der Post,Janet R. Vos,Arjen R. Mensenkamp,(unknown),Irıs D. Nagtegaal,Nicoline Hoogerbrugge,Richarda M. de Voer,Marjolijn J. L. Ligtenberg	5
5	The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First? 2023 ·Gynecologic Oncology ·(unknown),Marjolijn J. L. Ligtenberg,Janet R. Vos,Jozé Braspenning,Margreet G.E.M. Ausems,Marian J.E. Mourits,Joanne A. de Hullu,Eddy Adang,Nicoline Hoogerbrugge	6
6	Yield of annual endometrial cancer surveillance in women with PTEN Hamartoma Tumor Syndrome 2023 ·European Journal of Medical Genetics ·(unknown),(unknown),Joanne A. de Hullu,Janet R. Vos,Nicoline Hoogerbrugge,Anne M. van Altena	2
7	The yield and effectiveness of breast cancer surveillance in women with PTEN Hamartoma Tumor Syndrome 2022 ·Cancer ·(unknown),(unknown),Janet R. Vos,Peter Bult,Ritse M. Mann,Nicoline Hoogerbrugge	8
8	Red flags for early recognition of adult patients with PTEN Hamartoma Tumour Syndrome 2021 ·European Journal of Medical Genetics ·(unknown),Jolanda Schieving,Janneke Schuurs-Hoeijmakers,Janet R. Vos,Nicoline Hoogerbrugge	12
9	Evaluation of yield and experiences of age‐related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome 2020 ·International Journal of Cancer ·Janet R. Vos,(unknown),Liesbeth Spruijt,Riki W. Willems,(unknown),Arjen R. Mensenkamp,Edward M. Leter,Irıs D. Nagtegaal,Marjolijn J. L. Ligtenberg,Nicoline Hoogerbrugge,(unknown)	16
10	Parelsnoer Institute Biobank Hereditary Colorectal Cancer: A Joint Infrastructure for Patient Data and Biomaterial on Hereditary Colorectal Cancer in the Netherlands 2019 ·SHILAP Revista de lepidopterología ·Peggy Manders,Janet R. Vos,Richarda M. de Voer,(unknown),Rolf H. Sijmons,(unknown),Fokke G. Terpstra,Manon C.W. Spaander,Wilma E. Mesker,Evelien Dekker,Nicoline Hoogerbrugge	0
11	The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position? 2018 ·European Journal of Human Genetics ·(unknown),(unknown),Annemieke van der Hout,Jan C. Oosterwijk,Janet R. Vos,Peter Devilee,Klaartje van Engelen,Hanne Meijers‐Heijboer,Rob B. van der Luijt,Mieke Kriege,Arjen R. Mensenkamp,Matti A. Rookus,(unknown),Marian J.E. Mourits,Geertruida H. de Bock	6
12	[European Reference Networks for rare diseases]. 2018 ·PubMed ·Janet R. Vos,Wendy A.G. van Zelst–Stams,Nicoline Hoogerbrugge	1
13	Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes 2018 ·Familial Cancer ·(unknown),Janet R. Vos,(unknown),Claas Röhl,N.A. Geverink,Nicoline Hoogerbrugge	15
14	Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers 2016 ·Cancer Epidemiology Biomarkers & Prevention ·Janet R. Vos,Jan C. Oosterwijk,Cora M. Aalfs,Matti A. Rookus,Muriel A. Adank,Annemarie H. van der Hout,Christi J. van Asperen,E. Gómez,Arjen R. Mensenkamp,Agnes Jager,Margreet G.E.M. Ausems,Marian J.E. Mourits,Geertruida H. de Bock	5
15	Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1 / 2 mutation carriers and decreasing risk in the general population 2015 ·Gynecologic Oncology ·Janet R. Vos,Marian J.E. Mourits,(unknown),Liesbeth Jansen,Jan C. Oosterwijk,Geertruida H. de Bock	1
16	Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk 2015 ·Maturitas ·(unknown),Marian J.E. Mourits,Janet R. Vos,Dorina M. van der Kolk,Liesbeth Jansen,Jan C. Oosterwijk,Geertruida H. de Bock	4
17	Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands 2014 ·Cancer Epidemiology Biomarkers & Prevention ·Janet R. Vos,(unknown),Dorina M. van der Kolk,Marian J.E. Mourits,Matti A. Rookus,Flora E. van Leeuwen,Margriet Collée,Christi J. van Asperen,Arjen R. Mensenkamp,Margreet G.E.M. Ausems,Theo A.M. van Os,Hanne Meijers‐Heijboer,E. Gómez,Hans F. A. Vasen,Richard M. Brohet,Annemarie H. van der Hout,Liesbeth Jansen,Jan C. Oosterwijk,Geertruida H. de Bock	8
18	Relevance and efficacy of breast cancer screening inBRCA1andBRCA2mutation carriers above 60 years: A national cohort study 2014 ·International Journal of Cancer ·Sepideh Saadatmand,Janet R. Vos,Maartje J. Hooning,Jan C. Oosterwijk,Linetta B. Koppert,Geertruida H. de Bock,Margreet G.E.M. Ausems,Christi J. van Asperen,Cora M. Aalfs,E. Gómez,Hanne Meijers‐Heijboer,Nicoline Hoogerbrugge,(unknown),Caroline Seynaeve,Cornelis Verhoef,Matti A. Rookus,Madeleine M.A. Tilanus‐Linthorst	11
19	Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study 2014 ·Data Archiving and Networked Services (DANS) ·(unknown),Janet R. Vos,Maartje J. Hooning,Jan C. Oosterwijk,Linetta B. Koppert,Geertruida H. de Bock,C. Seynaeve,Matti A. Rookus,Madeleine M.A. Tilanus‐Linthorst,(unknown)	2
20	Proven non-carriers in BRCA families have an earlier age of onset of breast cancer 2013 ·European Journal of Cancer ·Janet R. Vos,Geertruida H. de Bock,(unknown),Dorina M. van der Kolk,Liesbeth Jansen,Marian J.E. Mourits,Jan C. Oosterwijk	15

About Janet R. Vos

Janet R. Vos is a scholar working on Reproductive Medicine, Genetics and Oncology, having authored 28 papers that have together received 220 indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (13 papers), Ovarian cancer diagnosis and treatment (7 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). The work is most often cited by research in Reproductive Medicine (40 citations), Cancer Research (54 citations) and Genetics (95 citations). Janet R. Vos has collaborated with scholars based in Netherlands, Italy and Philippines. Frequent co-authors include Nicoline Hoogerbrugge, Janneke Schuurs-Hoeijmakers, Marian J.E. Mourits, Geertruida H. de Bock, Jan C. Oosterwijk, Arjen R. Mensenkamp, Marjolijn J. L. Ligtenberg, Margreet G.E.M. Ausems, Jakob de Vries and Jolanda Schieving. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact